NCT00281879 · ADVERSE EVENTS
Adverse events
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.
- Collection time frame
- Not reported
- Other-event reporting threshold
- 5%
| Safety group | Serious events | Other events | Deaths |
|---|---|---|---|
| Cyclophosphamide (Cytoxan) and Total Body Irradiation (TBI) | 101 / 128 | 19 / 128 | Not reported / Not reported |
| Busulfan and Cyclophosphamide (Cytoxan) | 25 / 36 | 0 / 36 | Not reported / Not reported |
| BEAM Regimen | 17 / 20 | 2 / 20 | Not reported / Not reported |
| Low-Dose Fludarabine and TBI(for Second Stem Cell Donation) | 0 / 0 | 0 / 0 | Not reported / Not reported |
| Busulfan, Cyclophosphamide, and Fludarabine (Pediatric Only) | 5 / 6 | 0 / 6 | Not reported / Not reported |
| ATG For Cord Blood Transplants | 6 / 9 | 0 / 9 | Not reported / Not reported |
| DLI (Donor Leukocyte Infusion) | 0 / 0 | 0 / 0 | Not reported / Not reported |
| Cyclophosphamide, Etoposide (VP16) and TBI (Pediatric Only) | 1 / 1 | 0 / 1 | Not reported / Not reported |
Serious adverse events
- organ System
- Blood and lymphatic system disorders
- stats
- group Id
- EG000
- num Affected
- 3
- num At Risk
- 128
- group Id
- EG001
- num Affected
- 1
- num At Risk
- 36
- group Id
- EG002
- num Affected
- 0
- num At Risk
- 20
- group Id
- EG003
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG004
- num Affected
- 0
- num At Risk
- 6
- group Id
- EG005
- num Affected
- 0
- num At Risk
- 9
- group Id
- EG006
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG007
- num Affected
- 0
- num At Risk
- 1
- num Events
- 0
- term
- Staph Sepsis
- organ System
- Psychiatric disorders
- stats
- group Id
- EG000
- num Affected
- 1
- num At Risk
- 128
- group Id
- EG001
- num Affected
- 1
- num At Risk
- 36
- group Id
- EG002
- num Affected
- 0
- num At Risk
- 20
- group Id
- EG003
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG004
- num Affected
- 0
- num At Risk
- 6
- group Id
- EG005
- num Affected
- 0
- num At Risk
- 9
- group Id
- EG006
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG007
- num Affected
- 0
- num At Risk
- 1
- num Events
- 0
- term
- Altered mental status
- organ System
- Respiratory, thoracic and mediastinal disorders
- stats
- group Id
- EG000
- num Affected
- 5
- num At Risk
- 128
- group Id
- EG001
- num Affected
- 1
- num At Risk
- 36
- group Id
- EG002
- num Affected
- 0
- num At Risk
- 20
- group Id
- EG003
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG004
- num Affected
- 0
- num At Risk
- 6
- group Id
- EG005
- num Affected
- 0
- num At Risk
- 9
- group Id
- EG006
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG007
- num Affected
- 0
- num At Risk
- 1
- num Events
- 0
- term
- Pneumonia
- organ System
- Respiratory, thoracic and mediastinal disorders
- stats
- group Id
- EG000
- num Affected
- 1
- num At Risk
- 128
- group Id
- EG001
- num Affected
- 0
- num At Risk
- 36
- group Id
- EG002
- num Affected
- 0
- num At Risk
- 20
- group Id
- EG003
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG004
- num Affected
- 0
- num At Risk
- 6
- group Id
- EG005
- num Affected
- 0
- num At Risk
- 9
- group Id
- EG006
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG007
- num Affected
- 0
- num At Risk
- 1
- num Events
- 0
- term
- Hypoxia
- organ System
- General disorders
- stats
- group Id
- EG000
- num Affected
- 101
- num At Risk
- 128
- group Id
- EG001
- num Affected
- 25
- num At Risk
- 36
- group Id
- EG002
- num Affected
- 17
- num At Risk
- 20
- group Id
- EG003
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG004
- num Affected
- 5
- num At Risk
- 6
- group Id
- EG005
- num Affected
- 6
- num At Risk
- 9
- group Id
- EG006
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG007
- num Affected
- 1
- num At Risk
- 1
- num Events
- 1
- term
- Death
- organ System
- Immune system disorders
- stats
- group Id
- EG000
- num Affected
- 0
- num At Risk
- 128
- group Id
- EG001
- num Affected
- 0
- num At Risk
- 36
- group Id
- EG002
- num Affected
- 1
- num At Risk
- 20
- group Id
- EG003
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG004
- num Affected
- 0
- num At Risk
- 6
- group Id
- EG005
- num Affected
- 0
- num At Risk
- 9
- group Id
- EG006
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG007
- num Affected
- 0
- num At Risk
- 1
- num Events
- 0
- term
- Fever
- organ System
- Gastrointestinal disorders
- stats
- group Id
- EG000
- num Affected
- 17
- num At Risk
- 128
- group Id
- EG001
- num Affected
- 13
- num At Risk
- 36
- group Id
- EG002
- num Affected
- 3
- num At Risk
- 20
- group Id
- EG003
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG004
- num Affected
- 1
- num At Risk
- 6
- group Id
- EG005
- num Affected
- 0
- num At Risk
- 9
- group Id
- EG006
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG007
- num Affected
- 0
- num At Risk
- 1
- num Events
- 0
- term
- Graft versus host disease (GVHD)
- organ System
- Respiratory, thoracic and mediastinal disorders
- stats
- group Id
- EG000
- num Affected
- 3
- num At Risk
- 128
- group Id
- EG001
- num Affected
- 2
- num At Risk
- 36
- group Id
- EG002
- num Affected
- 2
- num At Risk
- 20
- group Id
- EG003
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG004
- num Affected
- 1
- num At Risk
- 6
- group Id
- EG005
- num Affected
- 0
- num At Risk
- 9
- group Id
- EG006
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG007
- num Affected
- 1
- num At Risk
- 1
- term
- Acute Respiratory Distress Syndrome (ARDS)
- organ System
- Cardiac disorders
- stats
- group Id
- EG000
- num Affected
- 1
- num At Risk
- 128
- group Id
- EG001
- num Affected
- 0
- num At Risk
- 36
- group Id
- EG002
- num Affected
- 0
- num At Risk
- 20
- group Id
- EG003
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG004
- num Affected
- 0
- num At Risk
- 6
- group Id
- EG005
- num Affected
- 0
- num At Risk
- 9
- group Id
- EG006
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG007
- num Affected
- 0
- num At Risk
- 1
- num Events
- 0
- term
- Cardiac Problems
- organ System
- Blood and lymphatic system disorders
- stats
- group Id
- EG000
- num Affected
- 1
- num At Risk
- 128
- group Id
- EG001
- num Affected
- 0
- num At Risk
- 36
- group Id
- EG002
- num Affected
- 0
- num At Risk
- 20
- group Id
- EG003
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG004
- num Affected
- 0
- num At Risk
- 6
- group Id
- EG005
- num Affected
- 0
- num At Risk
- 9
- group Id
- EG006
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG007
- num Affected
- 0
- num At Risk
- 1
- num Events
- 0
- term
- Thrombocytopenia
- organ System
- General disorders
- stats
- group Id
- EG000
- num Affected
- 4
- num At Risk
- 128
- group Id
- EG001
- num Affected
- 2
- num At Risk
- 36
- group Id
- EG002
- num Affected
- 0
- num At Risk
- 20
- group Id
- EG003
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG004
- num Affected
- 0
- num At Risk
- 6
- group Id
- EG005
- num Affected
- 0
- num At Risk
- 9
- group Id
- EG006
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG007
- num Affected
- 0
- num At Risk
- 1
- num Events
- 0
- term
- Diarrhea
- organ System
- Blood and lymphatic system disorders
- stats
- group Id
- EG000
- num Affected
- 3
- num At Risk
- 128
- group Id
- EG001
- num Affected
- 1
- num At Risk
- 36
- group Id
- EG002
- num Affected
- 0
- num At Risk
- 20
- group Id
- EG003
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG004
- num Affected
- 0
- num At Risk
- 6
- group Id
- EG005
- num Affected
- 0
- num At Risk
- 9
- group Id
- EG006
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG007
- num Affected
- 0
- num At Risk
- 1
- num Events
- 0
- term
- Orthostatic Hypertension
Other reported adverse events
- organ System
- General disorders
- stats
- group Id
- EG000
- num Affected
- 8
- num At Risk
- 128
- group Id
- EG001
- num Affected
- 0
- num At Risk
- 36
- group Id
- EG002
- num Affected
- 2
- num At Risk
- 20
- group Id
- EG003
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG004
- num Affected
- 0
- num At Risk
- 6
- num Events
- 0
- group Id
- EG005
- num Affected
- 0
- num At Risk
- 9
- num Events
- 0
- group Id
- EG006
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG007
- num Affected
- 0
- num At Risk
- 1
- num Events
- 0
- term
- Headache
- organ System
- General disorders
- stats
- group Id
- EG000
- num Affected
- 11
- num At Risk
- 128
- group Id
- EG001
- num Affected
- 0
- num At Risk
- 36
- group Id
- EG002
- num Affected
- 0
- num At Risk
- 20
- group Id
- EG003
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG004
- num Affected
- 0
- num At Risk
- 6
- num Events
- 0
- group Id
- EG005
- num Affected
- 0
- num At Risk
- 9
- num Events
- 0
- group Id
- EG006
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG007
- num Affected
- 0
- num At Risk
- 1
- num Events
- 0
- term
- Nausea
Complete source fields
- event Groups
- description
- On admission day, you will start to take a drug called allopurinol which helps to protect your kidneys as your body works to discharge cells killed off by your chemotherapy and TBI. Allopurinol tablets will be given to you by mouth up to three times a day for 7 days. You will begin radiation therapy to your entire body at the start of your transplant treatment. This procedure is called TBI (total body irradiation). Radiation will be given to you 2 times a day for 3 or 4 days. After the radiation treatment, you will receive two doses of cyclophosphamide by vein (through a small plastic tube leading into the bloodstream). Each dose takes about 2 hours to administer. When you are given cyclophosphamide, you will also be given a medication called MESNA to help protect your bladder from damage. After you have completed the cyclophosphamide you will rest one day without any anti-cancer therapy.
- id
- EG000
- other Num Affected
- 19
- other Num At Risk
- 128
- serious Num Affected
- 101
- serious Num At Risk
- 128
- title
- Cyclophosphamide (Cytoxan) and Total Body Irradiation (TBI)
- description
- On admission day, you will start to take a drug called Dilantin, which is used to help prevent seizures while you receive your chemotherapy drugs. You will also start to take a drug called allopurinol,which helps to protect your kidneys as your body works to discharge cells killed off by your chemotherapy and TBI. Allopurinol tablets will be given to you by mouth up to three times a day for 7 days. You will begin the therapy with a drug called busulfan. This medicine is take by mouth four times per day for four days. After the oral busulfan treatment, you will receive two doses of cyclophosphamide over 2 hours by vein (through a small tube leading into the bloodstream). When you are given cyclophosphamide, you will also be given a medication called MESNA to help protect your bladder from damage. Subjects undergoing the Busulfan and Cyclophosphamide regimen will not have total body irradiation (TBI).
- id
- EG001
- other Num Affected
- 0
- other Num At Risk
- 36
- serious Num Affected
- 25
- serious Num At Risk
- 36
- title
- Busulfan and Cyclophosphamide (Cytoxan)
- description
- On the day of your admission, you will start to take a drug called allopurinol which helps to protect your kidneys as your body works to discharge cells killed off by your chemotherapy and TBI. Chemotherapy will begin on Day -6 with carmustine (BCNU), followed by etoposide (VP-16), cytosine arabinoside (ARA-C), and melphalan. This conditioning regimen is known as the BEAM regimen. The dose of this therapy is high enough to kill cancer cells but will also kill all of your normal blood forming cells. Subjects undergoing the BEAM regimen will not have total body irradiation (TBI).
- id
- EG002
- other Num Affected
- 2
- other Num At Risk
- 20
- serious Num Affected
- 17
- serious Num At Risk
- 20
- title
- BEAM Regimen
- description
- A conditioning regimen of low-dose fludarabine and TBI is used in the event that a second donation of hematopoietic stem cells is necessary. Chemotherapy with Fludarabine will begin 4 days prior to your transplant. This drug will be given through the catheter in your chest daily for 3 days. TBI (radiation) will be given to you on the day of your transplant. After your TBI, your donor's stem cells / bone marrow will be given to you through your catheter. The drugs cyclosporine and mycophenolate mofetil (MMF) will be given orally to help you accept your donor's cells.
- id
- EG003
- other Num Affected
- 0
- other Num At Risk
- 0
- serious Num Affected
- 0
- serious Num At Risk
- 0
- title
- Low-Dose Fludarabine and TBI(for Second Stem Cell Donation)
- description
- On the day of your admission you will start to take a drug called Dilantin which is used to help prevent seizures while you receive your chemotherapy drugs. You will also start to take a drug called allopurinol which helps to protect your kidneys as your body works to discharge cells killed off by your chemotherapy and TBI. On the next day, you will then begin your conditioning therapy with a drug called busulfan. This medicine will be given to you by an infusion into your bloodstream through a small tube in the vein of your arm four times per day for four days. After the busulfan treatment, you will receive 4 doses each of two drugs, cyclophosphamide (also known as Cytoxan) and fludarabine, over 2 hours into your vein.
- id
- EG004
- other Num Affected
- 0
- other Num At Risk
- 6
- serious Num Affected
- 5
- serious Num At Risk
- 6
- title
- Busulfan, Cyclophosphamide, and Fludarabine (Pediatric Only)
- description
- If you are undergoing a pre-transplant conditioning regimen prior to undergoing a cord blood transplant, you will receive a drug called ATG to improve your chances of engraftment and decrease your risk of graft versus host disease. You may receive ATG 3 times during your transplant regimen on days -3 through days -1 in addition to your pre-transplant conditioning therapy. Methylprednisolone will also be given during each dose of ATG to help reduce any reactions during infusion.
- id
- EG005
- other Num Affected
- 0
- other Num At Risk
- 9
- serious Num Affected
- 6
- serious Num At Risk
- 9
- title
- ATG For Cord Blood Transplants
- description
- Donor Leukocyte Infusions: You will receive DLI from your original transplant donor. This will be given through a vein , usually in your arm. It will be similar to getting a platelet or blood transfusion. You may require more than one DLI. The decision to give you another infusion will be determined by your condition, relapse status, GVHD and how much DLI you were given before. You may need chemotherapy and/or radiation to improve your disease status prior to additional DLI's.
- id
- EG006
- other Num Affected
- 0
- other Num At Risk
- 0
- serious Num Affected
- 0
- serious Num At Risk
- 0
- title
- DLI (Donor Leukocyte Infusion)
- description
- On the day after your admission, you will start receiving radiation therapy (TBI). Radiation will be given to you 2 times a day for 3 days. On the next day, you will then begin your chemotherapy with a drug called etoposide. This medicine will be given to you by an infusion into your bloodstream through a small tube in the vein of your arm for one day. After the etoposide treatment, on the next day you will receive cyclophosphamide (also known as Cytoxan) for 2 days. When you are given cyclophosphamide, you will also be given a medication called MESNA to help protect your bladder from damage. After you have completed the cyclophosphamide you will rest one day without any anti-cancer therapy. This allows your body time to remove and inactivate the chemotherapy. After a day of rest, you will be given your donor's cells.
- id
- EG007
- other Num Affected
- 0
- other Num At Risk
- 1
- serious Num Affected
- 1
- serious Num At Risk
- 1
- title
- Cyclophosphamide, Etoposide (VP16) and TBI (Pediatric Only)
- frequency Threshold
- 5
- other Events
- organ System
- General disorders
- stats
- group Id
- EG000
- num Affected
- 8
- num At Risk
- 128
- group Id
- EG001
- num Affected
- 0
- num At Risk
- 36
- group Id
- EG002
- num Affected
- 2
- num At Risk
- 20
- group Id
- EG003
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG004
- num Affected
- 0
- num At Risk
- 6
- num Events
- 0
- group Id
- EG005
- num Affected
- 0
- num At Risk
- 9
- num Events
- 0
- group Id
- EG006
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG007
- num Affected
- 0
- num At Risk
- 1
- num Events
- 0
- term
- Headache
- organ System
- General disorders
- stats
- group Id
- EG000
- num Affected
- 11
- num At Risk
- 128
- group Id
- EG001
- num Affected
- 0
- num At Risk
- 36
- group Id
- EG002
- num Affected
- 0
- num At Risk
- 20
- group Id
- EG003
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG004
- num Affected
- 0
- num At Risk
- 6
- num Events
- 0
- group Id
- EG005
- num Affected
- 0
- num At Risk
- 9
- num Events
- 0
- group Id
- EG006
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG007
- num Affected
- 0
- num At Risk
- 1
- num Events
- 0
- term
- Nausea
- serious Events
- organ System
- Blood and lymphatic system disorders
- stats
- group Id
- EG000
- num Affected
- 3
- num At Risk
- 128
- group Id
- EG001
- num Affected
- 1
- num At Risk
- 36
- group Id
- EG002
- num Affected
- 0
- num At Risk
- 20
- group Id
- EG003
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG004
- num Affected
- 0
- num At Risk
- 6
- group Id
- EG005
- num Affected
- 0
- num At Risk
- 9
- group Id
- EG006
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG007
- num Affected
- 0
- num At Risk
- 1
- num Events
- 0
- term
- Staph Sepsis
- organ System
- Psychiatric disorders
- stats
- group Id
- EG000
- num Affected
- 1
- num At Risk
- 128
- group Id
- EG001
- num Affected
- 1
- num At Risk
- 36
- group Id
- EG002
- num Affected
- 0
- num At Risk
- 20
- group Id
- EG003
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG004
- num Affected
- 0
- num At Risk
- 6
- group Id
- EG005
- num Affected
- 0
- num At Risk
- 9
- group Id
- EG006
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG007
- num Affected
- 0
- num At Risk
- 1
- num Events
- 0
- term
- Altered mental status
- organ System
- Respiratory, thoracic and mediastinal disorders
- stats
- group Id
- EG000
- num Affected
- 5
- num At Risk
- 128
- group Id
- EG001
- num Affected
- 1
- num At Risk
- 36
- group Id
- EG002
- num Affected
- 0
- num At Risk
- 20
- group Id
- EG003
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG004
- num Affected
- 0
- num At Risk
- 6
- group Id
- EG005
- num Affected
- 0
- num At Risk
- 9
- group Id
- EG006
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG007
- num Affected
- 0
- num At Risk
- 1
- num Events
- 0
- term
- Pneumonia
- organ System
- Respiratory, thoracic and mediastinal disorders
- stats
- group Id
- EG000
- num Affected
- 1
- num At Risk
- 128
- group Id
- EG001
- num Affected
- 0
- num At Risk
- 36
- group Id
- EG002
- num Affected
- 0
- num At Risk
- 20
- group Id
- EG003
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG004
- num Affected
- 0
- num At Risk
- 6
- group Id
- EG005
- num Affected
- 0
- num At Risk
- 9
- group Id
- EG006
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG007
- num Affected
- 0
- num At Risk
- 1
- num Events
- 0
- term
- Hypoxia
- organ System
- General disorders
- stats
- group Id
- EG000
- num Affected
- 101
- num At Risk
- 128
- group Id
- EG001
- num Affected
- 25
- num At Risk
- 36
- group Id
- EG002
- num Affected
- 17
- num At Risk
- 20
- group Id
- EG003
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG004
- num Affected
- 5
- num At Risk
- 6
- group Id
- EG005
- num Affected
- 6
- num At Risk
- 9
- group Id
- EG006
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG007
- num Affected
- 1
- num At Risk
- 1
- num Events
- 1
- term
- Death
- organ System
- Immune system disorders
- stats
- group Id
- EG000
- num Affected
- 0
- num At Risk
- 128
- group Id
- EG001
- num Affected
- 0
- num At Risk
- 36
- group Id
- EG002
- num Affected
- 1
- num At Risk
- 20
- group Id
- EG003
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG004
- num Affected
- 0
- num At Risk
- 6
- group Id
- EG005
- num Affected
- 0
- num At Risk
- 9
- group Id
- EG006
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG007
- num Affected
- 0
- num At Risk
- 1
- num Events
- 0
- term
- Fever
- organ System
- Gastrointestinal disorders
- stats
- group Id
- EG000
- num Affected
- 17
- num At Risk
- 128
- group Id
- EG001
- num Affected
- 13
- num At Risk
- 36
- group Id
- EG002
- num Affected
- 3
- num At Risk
- 20
- group Id
- EG003
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG004
- num Affected
- 1
- num At Risk
- 6
- group Id
- EG005
- num Affected
- 0
- num At Risk
- 9
- group Id
- EG006
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG007
- num Affected
- 0
- num At Risk
- 1
- num Events
- 0
- term
- Graft versus host disease (GVHD)
- organ System
- Respiratory, thoracic and mediastinal disorders
- stats
- group Id
- EG000
- num Affected
- 3
- num At Risk
- 128
- group Id
- EG001
- num Affected
- 2
- num At Risk
- 36
- group Id
- EG002
- num Affected
- 2
- num At Risk
- 20
- group Id
- EG003
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG004
- num Affected
- 1
- num At Risk
- 6
- group Id
- EG005
- num Affected
- 0
- num At Risk
- 9
- group Id
- EG006
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG007
- num Affected
- 1
- num At Risk
- 1
- term
- Acute Respiratory Distress Syndrome (ARDS)
- organ System
- Cardiac disorders
- stats
- group Id
- EG000
- num Affected
- 1
- num At Risk
- 128
- group Id
- EG001
- num Affected
- 0
- num At Risk
- 36
- group Id
- EG002
- num Affected
- 0
- num At Risk
- 20
- group Id
- EG003
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG004
- num Affected
- 0
- num At Risk
- 6
- group Id
- EG005
- num Affected
- 0
- num At Risk
- 9
- group Id
- EG006
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG007
- num Affected
- 0
- num At Risk
- 1
- num Events
- 0
- term
- Cardiac Problems
- organ System
- Blood and lymphatic system disorders
- stats
- group Id
- EG000
- num Affected
- 1
- num At Risk
- 128
- group Id
- EG001
- num Affected
- 0
- num At Risk
- 36
- group Id
- EG002
- num Affected
- 0
- num At Risk
- 20
- group Id
- EG003
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG004
- num Affected
- 0
- num At Risk
- 6
- group Id
- EG005
- num Affected
- 0
- num At Risk
- 9
- group Id
- EG006
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG007
- num Affected
- 0
- num At Risk
- 1
- num Events
- 0
- term
- Thrombocytopenia
- organ System
- General disorders
- stats
- group Id
- EG000
- num Affected
- 4
- num At Risk
- 128
- group Id
- EG001
- num Affected
- 2
- num At Risk
- 36
- group Id
- EG002
- num Affected
- 0
- num At Risk
- 20
- group Id
- EG003
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG004
- num Affected
- 0
- num At Risk
- 6
- group Id
- EG005
- num Affected
- 0
- num At Risk
- 9
- group Id
- EG006
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG007
- num Affected
- 0
- num At Risk
- 1
- num Events
- 0
- term
- Diarrhea
- organ System
- Blood and lymphatic system disorders
- stats
- group Id
- EG000
- num Affected
- 3
- num At Risk
- 128
- group Id
- EG001
- num Affected
- 1
- num At Risk
- 36
- group Id
- EG002
- num Affected
- 0
- num At Risk
- 20
- group Id
- EG003
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG004
- num Affected
- 0
- num At Risk
- 6
- group Id
- EG005
- num Affected
- 0
- num At Risk
- 9
- group Id
- EG006
- num Affected
- 0
- num At Risk
- 0
- num Events
- 0
- group Id
- EG007
- num Affected
- 0
- num At Risk
- 1
- num Events
- 0
- term
- Orthostatic Hypertension
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle